Source link : https://www.newshealth.biz/health-news/drug-survival-rates-in-pediatric-patients-with-hs-compared/
The drug survival for adalimumab is significantly higher than that of infliximab in pediatric patients with hidradenitis suppurativa (HS), results from a small single-center study showed. A previous study found that overall drug survival of adalimumab and infliximab in adults with HS at 12 and 24 months was 56.3% and 30.5%, and 58.3% and 48.6%, […]
Author : News Health
Publish date : 2024-11-27 14:27:20
Copyright for syndicated content belongs to the linked Source.